You are here

Tempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer Patients

CHICAGO, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced a collaboration with NYU School of Medicine aimed at improving outcomes for patients diagnosed with pancreatic cancer.

Pancreatic cancer is the third leading cause of cancer-related death in the United States and has a five-year survival rate of just nine percent. While personalized treatment approaches have led to improvements in treatment of other cancer types, the genetic mutations commonly seen in pancreatic cancer do not yet have “druggable” targets. A longstanding issue with pancreatic cancer is that patients with a similar diagnosis often have different outcomes, even when treated with the same therapies. Collecting molecular and clinical data for patients diagnosed with pancreatic cancer will allow researchers to identify patterns associated to the prognosis, diagnosis, targetability and side effects of the disease.

As part of the research collaboration, Tempus will work directly with world-renowned investigator Diane M. Simeone, MD, associate director for translational research at NYU Langone Health’s Perlmutter Cancer Center and head of its newly established Pancreatic Cancer Center at NYU Langone.

NYU Langone has collected data from roughly 500 patients with pancreatic cancer. Tempus will structure and analyze the data and will generate additional genomic data for a subset of those patients. The goal is to help cancer specialists uncover patterns that can predict how patients will respond to treatment.

“Our partnership with Tempus allows us to incorporate breakthroughs in genomics and technology to drive discoveries that have real impact on patients diagnosed with pancreatic cancer,” said Dr. Simeone.

“Generating and analyzing the data may provide evidence for alternative treatment choices where patients have seen little benefit with the current standard of care,” said Eric Lefkofsky, founder and CEO at Tempus. “It is likely that a combined analysis of the genomic and phenotypic patterns of pancreatic cancer will lead to the next big breakthroughs in this difficult to treat cancer.”

Perlmutter Cancer Center is one of only 48 Comprehensive Cancer Centers in the U.S. designated by the National Cancer Institute.

Tempus is currently working with a number of NCI designated Comprehensive Cancer Centers on pancreatic cancer projects aimed at improving outcomes for patients diagnosed with this challenging disease.

About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.

About New York University Langone Health:
NYU Langone Health is one of the nation's premier centers for excellence in clinical care, biomedical research, and medical education. Located in the heart of Manhattan, NYU Langone is composed of five hospitals—Tisch Hospital, its flagship acute care facility; Rusk Rehabilitation; the Hospital for Joint Diseases, the Medical Center's dedicated inpatient orthopaedic hospital; NYU Langone Hospital - Brooklyn, a full-service, 450-bed teaching hospital located in Brooklyn, and Hassenfeld Children's Hospital, a comprehensive pediatric hospital supporting a full array of children's health services across the organization. Also part of NYU Langone Health is NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history, and the Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute–designated cancer center. NYU Langone Health’s trifold mission to serve, teach, and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education, and research.

Tempus:
Clo Ewing 
clo@tempus.com

Thursday, January 25, 2018 - 10:30

More Headlines

Conversely, Kids Who Need Drugs Go Untreated
May Reduce the Need for Open-Heart Surgery
NDEA, a Known Carcinogen, Discovered During FDA Testing
Cleared for Adults with Relapsed or Refractory Disease
Approved as Maintenance Treatment for Opioid Dependence
Says Company’s OxyContin Had “Significant Role” in Opioid Epidemic
Study Uses Experimental Software to Decode Variations in Mood
Mixup with Losartan Discovered in Bottles